Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Novavax stock | 107.04

Own Novavax stock in just a few minutes.

Posted

Fact checked

Novavax, Inc is a biotechnology business based in the US. Novavax shares (NVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Novavax employs 522 staff and has a trailing 12-month revenue of around USD$204.8 million.

How to buy shares in Novavax

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Novavax. Find the stock by name or ticker symbol: NVAX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Novavax reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$107.04, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Novavax, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Novavax. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Novavax's share price?

Since the stock market crash in March caused by coronavirus, Novavax's share price has had significant positive movement.

Its last market close was USD$107.04, which is 92.79% up on its pre-crash value of USD$7.72 and 1,609.90% up on the lowest point reached during the March crash when the shares fell as low as USD$6.26.

If you had bought USD$1,000 worth of Novavax shares at the start of February 2020, those shares would have been worth USD$1,580.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$15,717.75.

Novavax share price

Use our graph to track the performance of NVAX stocks over time.

Novavax shares at a glance

Information last updated 2020-11-23.
Latest market close USD$107.04
52-week range USD$3.6518 - USD$189.4
50-day moving average USD$95.3337
200-day moving average USD$95.6609
Wall St. target price USD$186.2
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-8.597

Buy Novavax shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Novavax stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Novavax price performance over time

Historical closes compared with the close of $107.04 from 2020-10-16

1 week (2020-11-19) 23.89%
1 month (2020-10-29) 22.15%
3 months (2020-08-28) -0.65%
6 months (2020-05-29) 132.49%
1 year (2019-11-29) 2,107.01%
2 years (2018-11-29) 5,278.89%
3 years (2017-11-29) 7,888.06%
5 years (2015-11-27) 1,271.43%

Novavax financials

Revenue TTM USD$204.8 million
Gross profit TTM USD$-95,180,000
Return on assets TTM -8.19%
Return on equity TTM -468.16%
Profit margin -133.1%
Book value $1.691
Market capitalisation USD$6.1 billion

TTM: trailing 12 months

Shorting Novavax shares

There are currently 8.0 million Novavax shares held short by investors – that's known as Novavax's "short interest". This figure is 7.7% up from 7.4 million last month.

There are a few different ways that this level of interest in shorting Novavax shares can be evaluated.

Novavax's "short interest ratio" (SIR)

Novavax's "short interest ratio" (SIR) is the quantity of Novavax shares currently shorted divided by the average quantity of Novavax shares traded daily (recently around 2.9 million). Novavax's SIR currently stands at 2.73. In other words for every 100,000 Novavax shares traded daily on the market, roughly 2730 shares are currently held short.

However Novavax's short interest can also be evaluated against the total number of Novavax shares, or, against the total number of tradable Novavax shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novavax's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Novavax shares in existence, roughly 130 shares are currently held short) or 0.1276% of the tradable shares (for every 100,000 tradable Novavax shares, roughly 128 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novavax.

Find out more about how you can short Novavax stock.

Novavax share dividends

We're not expecting Novavax to pay a dividend over the next 12 months.

Have Novavax's shares ever split?

Novavax's shares were split on a 1:20 basis on 10 May 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novavax shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Novavax shares which in turn could have impacted Novavax's share price.

Novavax share price volatility

Over the last 12 months, Novavax's shares have ranged in value from as little as $3.6518 up to $189.4. A popular way to gauge a stock's volatility is its "beta".

NVAX.US volatility(beta: 1.64)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novavax's is 1.6392. This would suggest that Novavax's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Novavax overview

Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site